Diabetic Retinopathy Clinical Trials

Find Diabetic Retinopathy Clinical Trials Near You

CRIMSON: A Multicentre, Randomised, Sham-controlled (and Active Controlled in the USA), Double-masked, 72-week Trial to Study the Safety, Tolerability, Pharmacokinetics, and Efficacy of 3 Dosing Regimens of Intravitreal BI 764524 in Patients With Moderate to Severe Non-proliferative Diabetic Retinopathy

Status: Recruiting
Location: See all (90) locations...
Intervention Type: Drug
Study Type: Interventional
Study Phase: Phase 2
SUMMARY

This study is open to adults with diabetic retinopathy. People who have non-proliferative diabetic retinopathy of moderate or high severity can join the study. The purpose of this study is to find out whether a medicine called BI 764524 helps people with diabetic retinopathy. The study also aims to find a suitable treatment plan for BI 764524. Participants are put into 5 groups by chance. Participants in groups 1, 2, and 3 get BI 764524. Over 1 year, they get a different number of injections of the same dose of BI 764524 injected into 1 eye. During some visits, participants may get a sham control, which is done like an eye injection but without a needle, so that participants will not know how many injections of BI 764524 they received. Participants in group 4 only get a sham control. Participants in group 5 (only in the USA) get aflibercept or sham injections during some visits. Aflibercept is a medicine already used to treat diabetic retinopathy. Participants are in the study for one and a half years. During this time, they visit the study site at least 16 times. During this time, doctors regularly do eye exams and visual tests to assess the severity of participants' eye condition. After 1 year of treatment, researchers look at the number of participants with eye improvements. To do so, they compare eye damage and certain severe eye problems between the groups of participants. The doctors also regularly check participants' health and take note of any unwanted effects.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: f
View:

• Diagnosis of diabetes mellitus (DM) under regular treatment with Haemoglobin A1c (HbA1c) (glycated haemoglobin) (HbA1c) \<12%; DM should be under regular investigation by a trained specialist as per local standard of care prior to and during the trial

• Age ≥18 years at time of signing Informed Consent Form (ICF)

∙ Ocular inclusion criteria: study eye

• Moderate to severe non-proliferative diabetic retinopathy (NPDR) (Diabetic Retinopathy Severity Scale (DRSS) level 43 to 53) as assessed by Ultra-widefield colour fundus photography (UWF-CFP) images (within the 7-field grid) and confirmed by the central reading centre (CRC) at screening. Patient staged at DRSS level of 43 based on UWF-CFP images can be included only if:

‣ They are participating in the standard 7-field CFP sub-study of the trial, and

⁃ They are staged as DRSS level of 47 to 53 on standard 7-field CFP imaging, as confirmed by the CRC at screening.

• Ultra-widefield fluorescein angiography (UWF-FA) image gradable for presence of retinal non-perfusion (RNP) as confirmed by the CRC at screening

• Visual acuity: best corrected visual acuity (BCVA) letter score of ≥49 letters (approximate Snellen equivalent of 20/100 or better) using ETDRS chart at starting distance of 4 meter (m) at screening and reconfirmed at baseline

• Sufficiently clear ocular media, adequate pupillary dilation, and fixation to permit quality fundus imaging

Locations
United States
Arizona
Associated Retina Consultants, Ltd.
ACTIVE_NOT_RECRUITING
Phoenix
California
California Retina Consultants-Bakersfield-65523
ACTIVE_NOT_RECRUITING
Bakersfield
Retina-Vitreous Associates Medical Group
ACTIVE_NOT_RECRUITING
Beverly Hills
Retinal Diagnostic Center
COMPLETED
Campbell
The Retina Partners
ACTIVE_NOT_RECRUITING
Encino
Lugene Eye Institute
ACTIVE_NOT_RECRUITING
Glendale
Retina Associates of Southern California
ACTIVE_NOT_RECRUITING
Huntington Beach
Byers Eye Institute
COMPLETED
Palo Alto
California Eye Specialists Medical Group Inc
ACTIVE_NOT_RECRUITING
Pasadena
Retinal Consultants Medical Group
ACTIVE_NOT_RECRUITING
Sacramento
Retinal Consultants Medical Group
ACTIVE_NOT_RECRUITING
Sacramento
California Retina Consultants-Santa Maria-65510
ACTIVE_NOT_RECRUITING
Santa Maria
Bay Area Retina Associates - Walnut Creek
ACTIVE_NOT_RECRUITING
Walnut Creek
Colorado
Colorado Retina Associates
ACTIVE_NOT_RECRUITING
Lakewood
Connecticut
Retina Group of New England, PC
COMPLETED
Waterford
Florida
Florida Retina Institute
RECRUITING
Jacksonville
Florida Retina Consultants
ACTIVE_NOT_RECRUITING
Lakeland
East Florida Eye Institute
ACTIVE_NOT_RECRUITING
Stuart
Center for Retina and Macular Disease
ACTIVE_NOT_RECRUITING
Winter Haven
Hawaii
Retina Consultants Of Hawaii
ACTIVE_NOT_RECRUITING
‘aiea
Maryland
Cumberland Valley Retina Consultants
ACTIVE_NOT_RECRUITING
Hagerstown
Maine
Maine Eye Center
ACTIVE_NOT_RECRUITING
Portland
Mississippi
Deep Blue Retina Clinical Research PLLC
ACTIVE_NOT_RECRUITING
Southaven
New Jersey
NJRetina
ACTIVE_NOT_RECRUITING
Teaneck
New York
Long Island Vitreoretinal Consultants
COMPLETED
Great Neck
Retina Vitreous Surgeons of Central NY, PC
ACTIVE_NOT_RECRUITING
Liverpool
Ohio
University Hospitals Cleveland Medical Center
ACTIVE_NOT_RECRUITING
Cleveland
Oregon
EyeHealth Northwest
COMPLETED
Portland
South Carolina
Charleston Neuroscience Institute - Ladson
COMPLETED
Ladson
Tennessee
Tennessee Retina
ACTIVE_NOT_RECRUITING
Nashville
Texas
Austin Clinical Research, LLC
ACTIVE_NOT_RECRUITING
Austin
Austin Retina Associates
ACTIVE_NOT_RECRUITING
Austin
Retina Research Center, PLLC
ACTIVE_NOT_RECRUITING
Austin
Retina Consultants of Texas
ACTIVE_NOT_RECRUITING
Katy
Valley Retina Institute, PA
COMPLETED
Mcallen
Austin Retina Associates
COMPLETED
Round Rock
Medical Center Ophthalmology Associates
ACTIVE_NOT_RECRUITING
San Antonio
Retina Consultants of Texas
ACTIVE_NOT_RECRUITING
San Antonio
Retina Consultants of Texas - Schertz
COMPLETED
Schertz
Utah
Retina Associates of Utah
RECRUITING
Salt Lake City
Other Locations
Germany
Universitätsklinikum Bonn AöR
COMPLETED
Bonn
Universitätsmedizin der Johannes Gutenberg-Universität Mainz
ACTIVE_NOT_RECRUITING
Mainz
Diakonie Klinikum Dietrich Bonhoeffer GmbH
COMPLETED
Neubrandenburg
Universitätsklinikum Tübingen
COMPLETED
Tübingen
Universitätsklinikum Ulm
COMPLETED
Ulm
Hungary
Budapest Retina Associations Kft.
ACTIVE_NOT_RECRUITING
Budapest
Jahn Ferenc Del-Pest Hospital
COMPLETED
Budapest
Semmelweis University
COMPLETED
Budapest
University Debrecen Hospital
COMPLETED
Debrecen
Nozologen Kft.
ACTIVE_NOT_RECRUITING
Pécs
Zala Megyei Szent Rafael Korhaz
ACTIVE_NOT_RECRUITING
Zala
Italy
Azienda Ospedaliero Universitaria Careggi
ACTIVE_NOT_RECRUITING
Florence
Fondazione IRCCS Ca'Granda-Ospedale Maggiore Policlinico
ACTIVE_NOT_RECRUITING
Milan
Ospedale San Raffaele S.r.l.
COMPLETED
Milan
Azienda Ospedaliera Universitaria Federico II
ACTIVE_NOT_RECRUITING
Naples
IRCCS Fondazione Bietti
COMPLETED
Roma
Istituto Clinico Humanitas
ACTIVE_NOT_RECRUITING
Rozzano
Ospedali Riuniti di Ancona
ACTIVE_NOT_RECRUITING
Torrette Di Ancona
Japan
Akita University Hospital
COMPLETED
Akita
Hyogo Prefectural Amagasaki General Medical Center
ACTIVE_NOT_RECRUITING
Amagasaki-shi
Hayashi Eye Hospital
ACTIVE_NOT_RECRUITING
Fukuoka
Fukushima Medical University Hospital
ACTIVE_NOT_RECRUITING
Fukushima
Tokyo Medical University Hachioji Medical Center
ACTIVE_NOT_RECRUITING
Hachioji-shi
Kagawa University Hospital
COMPLETED
Kagawa, Kita-gun
Kagoshima University Hospital
COMPLETED
Kagoshima
Nara Medical University Hospital
COMPLETED
Kashihara
Kobe University Hospital
COMPLETED
Kobe
Shinshu University Hospital
ACTIVE_NOT_RECRUITING
Matsumoto-shi
National Hospital Organization Tokyo Medical Center
ACTIVE_NOT_RECRUITING
Meguro-ku
Aichi Medical University Hospital
COMPLETED
Nagakute
Hyogo College of Medicine Hospital
ACTIVE_NOT_RECRUITING
Nishinomiya
Juntendo University Hospital
ACTIVE_NOT_RECRUITING
Tokyo
Poland
Klinika Okulistyczna
COMPLETED
Bydgoszcz
Centrum Diagnostyki i Mikrochirurgii Oka-Lens Sp. z o.o.
ACTIVE_NOT_RECRUITING
Olsztyn
Centrum Medyczne Piasta 47 sp. z o.o.
COMPLETED
Wałbrzych
Warsaw Ophthalmology Hospital
ACTIVE_NOT_RECRUITING
Warsaw
4. Military Clinical Hospital with Polyclinic SP ZOZ
COMPLETED
Wroclaw
Puerto Rico
Emanuelli Research & Development Center
ACTIVE_NOT_RECRUITING
Arecibo
Spain
Hospital Universitari de Bellvitge
COMPLETED
Barcelon
Hospital Clínico San Carlos
COMPLETED
Madrid
Hospital Universitario 12 de Octubre
ACTIVE_NOT_RECRUITING
Madrid
Hospital Universitari General de Catalunya
ACTIVE_NOT_RECRUITING
Sant Cugat Del Vallés
Hospital General Universitario de Valencia
ACTIVE_NOT_RECRUITING
Valencia
United Kingdom
Colchester Hospital
COMPLETED
Colchester
Royal Liverpool University Hospital
ACTIVE_NOT_RECRUITING
Liverpool
Central Middlesex Hospital
ACTIVE_NOT_RECRUITING
London
King's College Hospital
COMPLETED
London
Moorfields Eye Hospital
ACTIVE_NOT_RECRUITING
London
Western Eye Hospital
ACTIVE_NOT_RECRUITING
London
Royal Victoria Infirmary
ACTIVE_NOT_RECRUITING
Newcastle Upon Tyne
Contact Information
Primary
Boehringer Ingelheim
clintriage.rdg@boehringer-ingelheim.com
1-800-243-0127
Time Frame
Start Date: 2024-05-15
Estimated Completion Date: 2027-08-20
Participants
Target number of participants: 175
Treatments
Experimental: BI 764524
BI 764524
Sham_comparator: Sham comparator to BI 764524
Sham comparator to BI 764524
Active_comparator: Aflibercept (Eylea®) - US only
Aflibercept (Eylea®) - US only
Related Therapeutic Areas
Sponsors
Leads: Boehringer Ingelheim

This content was sourced from clinicaltrials.gov